Table 3.

Primary outcomes of patients included in the study.

	SC	Icatibant	iC1e/K	p	All Patients
TATD (days)	10.5 ± 7.1	11.0 ± 8.9	14.2 ± 10.1	0.62	11.9 ± 8.6
TIICU (days)	4.6 ± 8.9	6.2 ± 10.5	8.7 ± 11.8	0.71	6.5 ± 10.2
Deaths	1	0	1		2

Abbreviations: iC1e/K, inhibitor of C1 esterase/kallikrein; TATD, time from admission to discharge; TIICU, time in intensive care unit. One-way ANOVA/chi-square test (for all the variables in which the expected numbers that were too small no significance was calculated).